New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 24, 2014
10:51 EDTGILD, COHStocks with call strike movement; COH GILD
Coach (COH) November 39 call option implied volatility decreased 3% to 30, Gilead (GILD) January 110 call option implied volatility decreased 5% to 30 according to IVolatility.
News For COH;GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 28, 2015
16:05 EDTGILDGilead narrows FY15 adj product gross margin view to 88%-90% from 87%-90%
16:04 EDTGILDGilead reports Q2 antiviral product sales increased to $7.6B
Subscribe for More Information
16:03 EDTGILDGilead reports Q1 total product sales $8.1B
Total product sales for the second quarter of were $8.1B compared to $6.4B for the second quarter of 2014. Product sales in the U.S. were $5.6B compared to $4.8B for the second quarter of 2014. In Europe, product sales were $2B compared to $1.3B for the same period in 2014.
16:02 EDTGILDGilead raises FY15 net product sales view to $29B-$30B from $28B-$29B
Subscribe for More Information
16:01 EDTGILDGilead reports Q2 adjusted EPS $3.15, consensus $2.71
Subscribe for More Information
15:47 EDTGILDGilead July weekly 112 straddle priced for 6% movement
Subscribe for More Information
15:21 EDTGILDNotable companies reporting after market close
Subscribe for More Information
13:39 EDTGILDGilead technical notes before results
Subscribe for More Information
11:42 EDTGILDStocks with call strike movement; FB GILD
Subscribe for More Information
10:23 EDTCOHBMO Capital says high-end handbag makers to stay weak
High end handbag makers Coach (COH), Kate Spade (KATE) and Michael Kors (KORS) are continuing to struggle and their share prices are likely to remain weak, research firm BMO Capital wrote in a note to investors today. The firm significantly cut its price targets on all three names. WHAT'S NEW: Consumers are spending less on high-end handbags as they increase the amount they allocate to other areas, including travel, leisure and apparel, BMO Capital analyst John Morris stated. Consequently, the North American handbag market was expanding at a 5% rate at the end of June, down from a high single digit rate earlier this year, according to Morris. Meanwhile, competition within the space is mounting and handbag price wars are continuing, the analyst stated. Although handbag stocks have dropped significantly and their valuations appear attractive, they are "falling knives," the analyst warned. Assessing the status of specific companies, Morris says that Kate Spade has avoided implementing major price cuts on its products, though its comparative sales and "mind share" have suffered as a result of that decision and stores are displaying its products less prominently. Coach's stock suggests that investors expect the company's fundamentals to rebound, but Morris thinks that their optimism may be premature. The pace of the company's improvement "remains challenging," and it is likely to be hurt by a decline of U.S. tourism, he believes. Also likely to be hurt by declines in tourism is Michael Kors, the analyst stated. The prices of Michael Kors' products are being reduced by retailers, its gross margins are sinking and its watch business is weak, Morris warned. He reduced his price target on Kate Spade to $19 from $30, on Coach to $28 from $37 and on Michael Kors to $40 from $51. The analyst kept Market Perform ratings on all three stocks. PRICE ACTION: In early trading, Kate Spade was little changed at $18.75, Coach fell 0.5% to $30.60 and Michael Kors was fractionally higher at $39.17.
09:04 EDTCOHHandbag makers estimates, price targets lowered at BMO Capital
Subscribe for More Information
July 27, 2015
11:57 EDTGILDStocks with call strike movement; FB GILD
Subscribe for More Information
08:42 EDTGILDGilead July weekly volatility increases into Q2 and outlook
Subscribe for More Information
05:56 EDTGILDStocks with implied volatility movement; CRM GILD
Subscribe for More Information
July 24, 2015
06:27 EDTGILDGilead price target raised to $131 from $120 at Piper Jaffray
Subscribe for More Information
July 23, 2015
12:45 EDTGILDGilead July weekly volatility elevated into Q2 and outlook
Subscribe for More Information
10:00 EDTCOHOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:48 EDTCOHCoach upgraded to Neutral from Underperform at Buckingham
Subscribe for More Information
July 22, 2015
07:25 EDTCOHCoach price target lowered to $40 from $47 at Stifel
Stifel cut its price target on Coach as the firm believes that competition in the accessories category is increasing, causing a deceleration in the segment. However, the firm keeps a Buy rating on the stock.
July 21, 2015
14:12 EDTGILDGilead reports study of E/C/F/TAF met primary endpoint
Gilead Sciences announced detailed 48-week data from an open-label Phase 3 study evaluating its investigational once-daily single tablet regimen of elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg, or E/C/F/TAF, among 1,436 virologically suppressed adult patients switching from tenofovir disoproxil fumarate-containing regimens. The study met its primary endpoint by demonstrating non-inferiority of E/C/F/TAF to the TDF-based regimens at Week 48. The study also demonstrated statistical superiority among patients with HIV-1 RNA levels less than 50 copies/mL at Week 48 and statistically significant improvements in bone and renal laboratory parameters. These data were presented in an oral session at the 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention in Vancouver, Canada. Among the 1,436 patients who were randomized in the study, virologic success rates at Week 48 were higher in patients taking E/C/F/TAF, 97% versus 93% for all TDF-based regimens; difference in percentages: 4.1%, 95% CI: 1.6% to 6.7%. The rates of virologic failure were similar between the two arms, with E/C/F/TAF, 1.0% and TDF-based regimen, 1.3%. General safety was similar between the two arms through 48 weeks of treatment, with similar percentages of patients in each group having any adverse events. Adverse events leading to treatment discontinuation were more common among patients treated with a TDF-based regimen.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use